ECOR Stock Overview
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
electroCore, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.71 |
| 52 Week High | US$18.67 |
| 52 Week Low | US$5.32 |
| Beta | 0.50 |
| 1 Month Change | -3.08% |
| 3 Month Change | 36.25% |
| 1 Year Change | 109.47% |
| 3 Year Change | 66.93% |
| 5 Year Change | -14.85% |
| Change since IPO | -94.72% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By electroCore, Inc.'s (NASDAQ:ECOR) 27% Share Price Surge
Dec 18
electroCore, Inc. (NASDAQ:ECOR) Soars 34% But It's A Story Of Risk Vs Reward
Oct 08We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth
Sep 25electroCore sees Q3 revenue below consensus
Oct 14electroCore is issued 4 new U.S. patents in nVNS therapy
Sep 21electroCore sees Q2 revenue estimate higher than consensus
Jul 12We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth
Apr 29electroCore: Pioneering Bioelectronic Medicine
Jan 06electroCore completes sale of $1.4M of NOL tax benefits
Jun 09Shareholder Returns
| ECOR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.8% | 1.3% | -0.8% |
| 1Y | 109.5% | 15.0% | 25.2% |
Return vs Industry: ECOR exceeded the US Medical Equipment industry which returned 15% over the past year.
Return vs Market: ECOR exceeded the US Market which returned 25.2% over the past year.
Price Volatility
| ECOR volatility | |
|---|---|
| ECOR Average Weekly Movement | 13.5% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ECOR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ECOR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 68 | Dan Goldberger | www.electrocore.com |
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance.
electroCore, Inc. Fundamentals Summary
| ECOR fundamental statistics | |
|---|---|
| Market cap | US$102.12m |
| Earnings (TTM) | -US$12.69m |
| Revenue (TTM) | US$23.33m |
4.4x
P/S Ratio-8.1x
P/E RatioIs ECOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECOR income statement (TTM) | |
|---|---|
| Revenue | US$23.33m |
| Cost of Revenue | US$3.89m |
| Gross Profit | US$19.44m |
| Other Expenses | US$32.13m |
| Earnings | -US$12.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.94 |
| Gross Margin | 83.32% |
| Net Profit Margin | -54.40% |
| Debt/Equity Ratio | 0% |
How did ECOR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 23:26 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
electroCore, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Tyler Bussian | Brookline Capital Markets |
| Sean Lavin | BTIG |